Riskpilot← Back to searchSign inGet full accessPHARMACOM AS
ASActiveOrg 996931226Dalveien 86, 1391 VollenAll other professional, scientific and technical activities n.e.c. · NACE 7499Est. 20110 employees
Revenue 2024
NOK 0
EBITDA margin
—
-511% vs 2023
Equity ratio
34.1%
Financial strength
Net profit 2024
NOK -94K
-479% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -173K | -511% |
| Net profit | NOK -94K | -479% |
| Total assets | NOK 508K | -16% |
| Equity | NOK 173K | -47% |
| Employees | 0 | — |
Legal name
PHARMACOM AS
Org number
996931226
Legal form
Aksjeselskap
NACE code
7499 · All other professional, scientific and technical activities n.e.c.
Founded
18. mai 2011
Share capital
NOK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Fremstilling/salg av serviceprodukter og konsulentoppdrag innen helsesektoren, utleie av legemiddelkonsulenter og andre produkter som naturlig faller sammen med dette, herunder å delta i andre selskaper med lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre seg interessert i andre foretagender.
Address
Dalveien 86, 1391 Vollen
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 291 | 387 | 774 | 500 | 0 |
| Staff expenses | −0 | −0 | −19 | −12 | −5 |
| EBITDA | 4 | 156 | 379 | 42 | −173 |
| Depreciation & amort. | −0 | −0 | −0 | −8 | −8 |
| EBIT | 4 | 156 | 379 | 34 | −181 |
| Net financials | 0 | −0 | −0 | −0 | −0 |
| Profit before tax | 4 | 156 | 379 | 34 | −181 |
| Tax | 5 | 34 | 94 | 9 | −87 |
| Net profit | −1 | 122 | 285 | 25 | −94 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 76 | 191 | 602 | 604 | 508 |
| Equity | −141 | 15 | 300 | 325 | 173 |
| Long-term debt | 0 | 0 | 1 | 1 | 0 |
| Short-term debt | 217 | 176 | 302 | 278 | 335 |
| Total debt | 217 | 176 | 302 | 279 | 335 |
EBITDA margin
-17272900.0%
This company
15.8%
Market median
-109322252% vs market
20202024
Equity ratio
34.1%
This company
38.2%
Market median
+11% vs market
20202024
Return on equity
-54.2%
This company
18.4%
Market median
-395% vs market
20202024
Net profit margin
-9375900.0%
This company
8.1%
Market median
-115751952% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.93×
This company
0.62×
Market median
-211% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GR Deputy Member | Deputy Member | 2011 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2011 | |
| Board of Directors | 2011 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PHARMACOM AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Geir Rasmus Nøstdahl | Deputy Member | 0 companies |
| Arve André Nøstdahl | Chairman | 0 companies |
| Linda Merete Nøstdahl | Board of Directors | 0 companies |